Clinical Trials Browser

Phase 1/2 × NIH × Melphalan × Clear all

NCT05436418 2026-03-18

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT00334932 2014-01-10

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00840684 2011-05-13

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

Phase 1/2 Completed

Other hematologic neoplasm

Congenital Abnormalities, Leukemia

NCT00045136 2009-04-03

Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Phase 1/2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell